Akebia Therapeutics Management
Management criteria checks 4/4
Akebia Therapeutics' CEO is John Butler, appointed in Sep 2013, has a tenure of 10.67 years. total yearly compensation is $2.78M, comprised of 28.7% salary and 71.3% bonuses, including company stock and options. directly owns 0.7% of the company’s shares, worth $2.19M. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.
Key information
John Butler
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 28.7% |
| CEO tenure | 10.7yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Akebia highlights late-stage vadadustat kidney disease study results
Apr 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$796k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$98m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$3m | US$765k | -US$94m |
| Sep 30 2022 | n/a | n/a | -US$158m |
| Jun 30 2022 | n/a | n/a | -US$163m |
| Mar 31 2022 | n/a | n/a | -US$276m |
| Dec 31 2021 | US$3m | US$718k | -US$282m |
| Sep 30 2021 | n/a | n/a | -US$299m |
| Jun 30 2021 | n/a | n/a | -US$300m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$6m | US$696k | -US$385m |
| Sep 30 2020 | n/a | n/a | -US$391m |
| Jun 30 2020 | n/a | n/a | -US$386m |
| Mar 31 2020 | n/a | n/a | -US$268m |
| Dec 31 2019 | US$4m | US$648k | -US$280m |
| Sep 30 2019 | n/a | n/a | -US$245m |
| Jun 30 2019 | n/a | n/a | -US$217m |
| Mar 31 2019 | n/a | n/a | -US$193m |
| Dec 31 2018 | US$3m | US$595k | -US$144m |
| Sep 30 2018 | n/a | n/a | -US$68m |
| Jun 30 2018 | n/a | n/a | -US$65m |
| Mar 31 2018 | n/a | n/a | -US$53m |
| Dec 31 2017 | US$3m | US$543k | -US$74m |
Compensation vs Market: John's total compensation ($USD2.78M) is about average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Butler (59 yo)
10.7yrs
Tenure
US$2,775,123
Compensation
Mr. John P. Butler, MBA, serves as Non-Executive Director at Wren Therapeutics Limited since 2023. He has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 10.7yrs | US$2.78m | 0.70% $ 2.2m | |
| Senior VP & COO | no data | US$1.25m | 0.16% $ 508.0k | |
| Senior VP | 11.3yrs | US$1.05m | 0.19% $ 592.0k | |
| Senior VP of Research & Development and Chief Medical Officer | 4.8yrs | US$1.21m | 0.16% $ 510.8k | |
| Chief Accounting Officer | less than a year | no data | no data | |
| Senior VP & Chief Technical Officer | less than a year | no data | no data | |
| Vice President of Portfolio Strategy & Corporate Administration | 1.3yrs | no data | no data | |
| Senior Director of Investor & Corporate Communications | no data | no data | no data | |
| Senior VP & Chief People Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Legal & General Counsel | 2.3yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: AKBA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 10.8yrs | US$2.78m | 0.70% $ 2.2m | |
| Independent Director | 5.4yrs | US$145.79k | 0.032% $ 98.4k | |
| Independent Chairperson | 5.4yrs | US$171.63k | 0.050% $ 156.1k | |
| Independent Director | 3.3yrs | US$143.31k | 0.0065% $ 20.4k | |
| Independent Director | 2.5yrs | US$147.97k | 0.0065% $ 20.4k | |
| Independent Director | 5.4yrs | US$139.87k | 0.027% $ 85.1k | |
| Independent Director | 5.8yrs | US$151.50k | 0.031% $ 97.2k | |
| Independent Director | 4.1yrs | US$144.43k | 0.018% $ 56.2k |
5.4yrs
Average Tenure
63.5yo
Average Age
Experienced Board: AKBA's board of directors are considered experienced (5.4 years average tenure).